New oral drug targets 'undruggable' cancer mutations in major tumors
NCT ID NCT06895031
Summary
This study is testing an experimental oral medication called JYP0015 in adults with advanced cancers that have specific RAS mutations, including pancreatic, lung, and colorectal cancers. The trial aims to find a safe dose and see if the drug can shrink tumors in patients who have stopped responding to standard treatments. Researchers will enroll about 210 participants across multiple centers to evaluate both safety and effectiveness.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Beijing Cancer Hospital
RECRUITINGBeijing, Beijing Municipality, 100142, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.